BRAF and CD4+/CD56+ hematodermic neoplasm: However, mutations in the RAS signaling pathway, including NRAS, PTPN11, and BRAF, were detected in 33% of cases (7/21), highlighting the potential for therapeutic strategies targeting the RAS signaling pathway in BPDCN.